1. Scrip
  2. >>Focus On Asia
  3. >>India

Management team appointments at Biological E

 
• By Zoë Dann

Biological E (India), a manufacturer of vaccines, biologics and pharmaceutical products, has made three appointments to its management team: Dr Martin Reers is named senior vice-president of technical operations, having most recently served as vice-president of technology development global, manufacturing sciences at Novartis/Chiron Vaccines; Dr Gopalam Somasekhar joins as senior vice-president of development – he was previously associate director at Wyeth Vaccines; and Dr Krish Venkat is appointed senior vice-president of quality, having previously worked as consultant to US biotech and pharmaceutical companies on quality and regulatory issues, and vaccine development, as a principal at Anven Research.

Biological E (India), a manufacturer of vaccines, biologics and pharmaceutical products, has made three appointments to its management team: Dr Martin Reers is named senior vice-president of technical operations, having most recently served as vice-president of technology development global, manufacturing sciences at Novartis/Chiron Vaccines; Dr Gopalam Somasekhar joins as senior vice-president of development – he was previously associate director at Wyeth Vaccines; and Dr Krish Venkat is appointed senior vice-president of quality, having previously worked as consultant to US biotech and pharmaceutical companies on quality and regulatory issues, and vaccine development, as a principal at Anven Research.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.